10 results about "Secondary hypoparathyroidism" patented technology

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

The present invention relates to a process for the preparation of AMG416. A method for preparing AMG416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is an octa-amino acid selective peptide antagonist of the synthesized calcium-sensitive receptor. It has been developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorders (CKD-MBD).

The present invention relates to a process for the preparation of AMG416. A method for preparing AMG416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is an octa-amino acid selective peptide antagonist of the synthesized calcium-sensitive receptor. It has been developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorders (CKD-MBD).

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

The invention belongs to the technical field of chemical raw material medicines, and particularly relates to an aryl alkyl amine compound as well as a preparation method and application thereof. The structure of the aryl alkyl amine compound is shown as a formula I. Experiments prove that the allosteric agonist effect of the compound provided by the invention on a calcium-sensitive receptor is superior to or equivalent to that of Evocalpet, and the aryl alkyl amine compound has potential in preparation of drugs for treating secondary hyperparathyroidism. Formula I

Methods of preventing or mitigating loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT) are disclosed.

This application relates to the field of intelligent medicine, and particularly relates to a method, system and device for predicting EPH after parathyroidectomy based on images. It includes obtaining parathyroid images of a patient; extracting EPH highly correlated features based on the parathyroid images to predict EPH after surgery to obtain a prediction result; wherein, the construction process of the EPH highly correlated features is as follows: S1: obtaining a parathyroid image set, EPH grouping labels, and blood calcium concentration labels of the patient; S2: extracting primary features from the parathyroid image set based on the EPH grouping labels and blood calcium concentration labels; S3: performing feature screening on the primary features to obtain the EPH highly correlated features. This method predicts whether EPH occurs after parathyroidectomy for patients with secondary hyperparathyroidism through radiomics features, and has good clinical value.

Disclosed are methods of preventing or reducing loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT).

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.